Tema Etfs LLC Makes New $2.83 Million Investment in argenx SE (NASDAQ:ARGX)

Tema Etfs LLC acquired a new stake in argenx SE (NASDAQ:ARGX - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 4,598 shares of the company's stock, valued at approximately $2,828,000.

Other large investors have also recently added to or reduced their stakes in the company. GeoWealth Management LLC grew its holdings in shares of argenx by 56.3% during the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company's stock valued at $31,000 after acquiring an additional 18 shares in the last quarter. Whipplewood Advisors LLC acquired a new stake in argenx during the fourth quarter valued at $37,000. Global Retirement Partners LLC boosted its position in argenx by 369.2% during the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock valued at $38,000 after purchasing an additional 48 shares during the last quarter. FIL Ltd purchased a new position in argenx in the fourth quarter valued at about $38,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in argenx in the fourth quarter valued at about $38,000. Institutional investors and hedge funds own 60.32% of the company's stock.

argenx Stock Up 1.1%

NASDAQ ARGX traded up $6.64 during trading on Wednesday, hitting $584.95. The company's stock had a trading volume of 434,704 shares, compared to its average volume of 326,106. argenx SE has a 52 week low of $358.80 and a 52 week high of $678.21. The firm has a market cap of $35.72 billion, a P/E ratio of -664.72 and a beta of 0.57. The firm has a 50 day moving average price of $591.30 and a 200 day moving average price of $613.17.

argenx (NASDAQ:ARGX - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.32 by $0.26. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $748.34 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. On average, equities analysts expect that argenx SE will post 3.13 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Baird R W raised argenx from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, May 13th. Wedbush reaffirmed an "outperform" rating and set a $715.00 price objective on shares of argenx in a research report on Friday, April 11th. Wells Fargo & Company boosted their target price on shares of argenx from $723.00 to $741.00 and gave the stock an "overweight" rating in a research report on Friday, February 28th. Robert W. Baird upgraded shares of argenx from a "neutral" rating to an "outperform" rating and set a $680.00 price target on the stock in a report on Tuesday, May 13th. Finally, William Blair reaffirmed an "outperform" rating on shares of argenx in a research note on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, twenty have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $698.11.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.